SCHEMBL2648015

SCHEMBL2648015

CCCNS(=O)(=O)c1cnc(N)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.46
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
CA2 P00918 1/20 0.46
ADORA3 P0DMS8 1/20 0.44
SLC6A3 Q01959 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.39
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2D6 P10635 1/20 0.38
NOS1 P29475 1/20 0.36
ALDH1A1 P00352 2/20 0.35
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241669 0.80 SMN1; SMN2 (0.51) CA1CA12CA9CA2ADORA3
SCHEMBL2649270 0.78 ADORA3 (0.50) ADORA3SLC6A3SMN1; SMN2TSHRHTT
SCHEMBL1240657 0.76 SMN1; SMN2 (0.53) ADORA3SLC6A3SMN1; SMN2MEN1TSHR
SCHEMBL11605900 0.75 ADORA3 (0.51) ADORA3SLC6A3SMN1; SMN2TSHRHTT
SCHEMBL2648013 0.73 ADORA3 (0.46) ADORA3SLC6A3SMN1; SMN2MEN1KMT2A
SCHEMBL2649130 0.73 ADORA3 (0.46) ADORA3SLC6A3SMN1; SMN2MEN1KMT2A
SCHEMBL1062364 0.71 ADORA3 (0.55) ADORA3SLC6A3SMN1; SMN2TSHRLOXL2
SCHEMBL1938183 0.71 ADORA3 (0.41) ADORA3SLC6A3SMN1; SMN2TSHRLOXL2
SCHEMBL2647697 0.70 CA2 (0.54) CA1CA12CA9CA2ALDH1A1
SCHEMBL1241096 0.69 ADORA3 (0.56) CA1CA12CA9CA2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582769-B2 Dicycloalkyl urea glucokinase activators NOVO NORDISK A/S (DK) 2009-09-01 US disclosed
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-05-07 US disclosed
EP-1904466-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006760-A1 DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118501-A1 Dicycloalkyl Urea Glucokinase Activators GCK, GCKR, UCK2 CA1 3286/4885CA12 3349/4885CA9 1314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.